<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785521</url>
  </required_header>
  <id_info>
    <org_study_id>NCH04-2020</org_study_id>
    <nct_id>NCT04785521</nct_id>
  </id_info>
  <brief_title>Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery</brief_title>
  <official_title>Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain metastases (BM) represents a devastating clinical reality, carrying an estimated&#xD;
      survival time of less than one year. Number of reasons, including complicated tumor biology&#xD;
      and difficulties in modeling metastatic cancer in brain microenvironment, do hinder research&#xD;
      on this topic. BM are indeed the most frequent neoplasm in the central nervous system (CNS)&#xD;
      and is estimated that up to 14% of all newly diagnosed cancers will metastasize to the brain.&#xD;
      A number of reasons, including complicated tumor biology and difficulties in modeling&#xD;
      metastatic cancer in brain microenvironment, do hinder research on this topic. Present&#xD;
      knowledge regarding alterations in Glutamate (Glu) homeostasis and BM is poor. This study&#xD;
      aims at investigating Glu balance in BM patients and providing supporting evidence to the&#xD;
      identification of new putative biomarkers to be used as potential therapeutic targets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental procedure:&#xD;
&#xD;
      Serum levels of glutamic oxaloacetic transaminase (GOT1), glutamate Pyruvate Transaminase&#xD;
      (GPT) and lactate dehydrogenase (LDH) levels and serum glutamate, aspartate and lactate&#xD;
      levels of a total of 100 patients will be collected and divided in three different groups:&#xD;
&#xD;
        -  A: BM group (n=50), patients affected by BM from lung, breast and melanoma, candidates&#xD;
           to SRS&#xD;
&#xD;
        -  B: Control group 1 (n=25), patients with the same primary controlled tumors without nor&#xD;
           brain nor extracranial metastases&#xD;
&#xD;
        -  C: Control group 2 (n=25), patients with benign intracranial lesions candidates to SRS&#xD;
           treatment.&#xD;
&#xD;
      In A) and C) serum GOT1, GPT and LDH levels and serum glutamate, aspartate, lactate levels&#xD;
      will be evaluated before and after SRS treatment (at 3, 6 and 9 months follow-up).&#xD;
&#xD;
      In B) serum biomarkers levels will be only collected at baseline.&#xD;
&#xD;
      • Oncological and imaging data will be collected during follow-up in patients enrolled in the&#xD;
      present studies. MRI imaging will be performed at definite timepoints (baseline and 3, 6 and&#xD;
      9 months follow-up).&#xD;
&#xD;
      Serum levels of markers will be analyzed in each group and results will be compared between&#xD;
      them. Moreover, MRI changes and oncological relevant outcomes will be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum markers determination in newly diagnosed BM (lung, breast and melanoma) patients, before SRS treatment.</measure>
    <time_frame>Baseline (pre-SRS);</time_frame>
    <description>GOT1, GPT and LDH levels and serum glutamate, aspartate and lactate levels. All measures in mg/dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum markers determination in newly diagnosed BM (lung, breast and melanoma) patients, after SRS treatment.</measure>
    <time_frame>Baseline (pre-SRS) and at 3, 6 and 9 months</time_frame>
    <description>GOT1, GPT and LDH levels and serum glutamate, aspartate and lactate levels. All measures in mg/dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum markers determination in melanoma, lung or breast cancer patients without BM.</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparison of serum GOT1, GPT and LDH levels and serum glutamate, aspartate and lactate levels between BM and non-BM patients. All measures in mg/dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum markers determination in patients carrying benign intracranial lesions before and after SRS treatment.</measure>
    <time_frame>Baseline (pre-SRS) and at 3, 6 and 9 months</time_frame>
    <description>Comparison of serum GOT1, GPT and LDH levels and serum glutamate, aspartate and lactate levels between BM and benign lesion patients. All measures in mg/dl.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Studying correlation of serum markers levels with MRI changes following SRS-GK</measure>
    <time_frame>3, 6 and 9 months</time_frame>
    <description>Correlation between trends of markers and incidence of MRI changes.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Brain Metastases, Adult</condition>
  <arm_group>
    <arm_group_label>BM patients</arm_group_label>
    <description>Adult patients carrying new diagnosed BM confirmed by MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No BM patients</arm_group_label>
    <description>Adult patients carrying extracranial tumor without BM as confirmed by MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign lesion patients</arm_group_label>
    <description>Adult patients carrying intracranial extra-axial tumor as as confirmed by MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiosurgery</intervention_name>
    <description>Gamma Knife stereotactic radiosurgery (SRS-GK)</description>
    <arm_group_label>BM patients</arm_group_label>
    <arm_group_label>Benign lesion patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.</description>
    <arm_group_label>BM patients</arm_group_label>
    <arm_group_label>Benign lesion patients</arm_group_label>
    <arm_group_label>No BM patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Target group:&#xD;
&#xD;
        Adult patients affected by melanoma, breast or lung cancer BM of new diagnosis as confirmed&#xD;
        by MRI ongoing SRS-GK treatment.&#xD;
&#xD;
        Control group 1:&#xD;
&#xD;
        Adult patients affected by melanoma, breast or lung cancer without BM.&#xD;
&#xD;
        Control group 2:&#xD;
&#xD;
        Adult patients affected by intracranial extra-axial benign tumor as confirmed by MRI&#xD;
        ongoing SRS-GK treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (Target group)&#xD;
&#xD;
          -  Adult patients carrying melanoma, breast or lung cancer BM of new diagnosis&#xD;
&#xD;
          -  Patients eligible to SRS-GK treatment&#xD;
&#xD;
        Inclusion Criteria (Control group 1)&#xD;
&#xD;
        - Adult patients carrying melanoma, breast or lung cancer without BM&#xD;
&#xD;
        Inclusion Criteria (Control group 2)&#xD;
&#xD;
          -  Adult patients carrying intracranial extra-axial benign tumor&#xD;
&#xD;
          -  Patients eligible to SRS-GK treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute or chronic liver disease&#xD;
&#xD;
          -  Severe anemia (Hb &lt;8g/dl)&#xD;
&#xD;
          -  Pregnant or breastfeeding patient&#xD;
&#xD;
          -  Pediatric patients&#xD;
&#xD;
          -  Patients not able to express informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pietro Mortini, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Sincinelli</last_name>
    <phone>00390226435568</phone>
    <email>sincinelli.laura@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS San Raffaele Scientific Institute</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sincinelli</last_name>
      <phone>003926435568</phone>
      <email>sincinelli.laura@hsr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Lowery FJ, Yu D. Brain metastasis: Unique challenges and open opportunities. Biochim Biophys Acta Rev Cancer. 2017 Jan;1867(1):49-57. doi: 10.1016/j.bbcan.2016.12.001. Epub 2016 Dec 6. Review.</citation>
    <PMID>27939792</PMID>
  </reference>
  <reference>
    <citation>Franzin A, Snider S, Picozzi P, Bolognesi A, Serra C, Vimercati A, Passarin O, Mortini P. Evaluation of different score index for predicting prognosis in gamma knife radiosurgical treatment for brain metastasis. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):707-13. doi: 10.1016/j.ijrobp.2008.08.062. Epub 2008 Dec 25.</citation>
    <PMID>19095375</PMID>
  </reference>
  <reference>
    <citation>Robert SM, Sontheimer H. Glutamate transporters in the biology of malignant gliomas. Cell Mol Life Sci. 2014 May;71(10):1839-54. doi: 10.1007/s00018-013-1521-z. Epub 2013 Nov 27. Review.</citation>
    <PMID>24281762</PMID>
  </reference>
  <reference>
    <citation>Miladinovic T, Nashed MG, Singh G. Overview of Glutamatergic Dysregulation in Central Pathologies. Biomolecules. 2015 Nov 11;5(4):3112-41. doi: 10.3390/biom5043112. Review.</citation>
    <PMID>26569330</PMID>
  </reference>
  <reference>
    <citation>Sharma MK, Seidlitz EP, Singh G. Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun. 2010 Jan 1;391(1):91-5. doi: 10.1016/j.bbrc.2009.10.168. Epub 2009 Nov 5.</citation>
    <PMID>19896463</PMID>
  </reference>
  <reference>
    <citation>Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, McCabe BD, Galván JA, Robinson HPC, Zlobec I, Ciriello G, Hanahan D. Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature. 2019 Sep;573(7775):526-531. doi: 10.1038/s41586-019-1576-6. Epub 2019 Sep 18.</citation>
    <PMID>31534217</PMID>
  </reference>
  <reference>
    <citation>Willard SS, Koochekpour S. Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications. Int J Biol Sci. 2013 Aug 9;9(7):728-42. doi: 10.7150/ijbs.6475. eCollection 2013. Review.</citation>
    <PMID>23983606</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Pietro Mortini, MD, Prof.</investigator_full_name>
    <investigator_title>Head of department</investigator_title>
  </responsible_party>
  <keyword>Brain metastases</keyword>
  <keyword>Glutamate</keyword>
  <keyword>Stereotactic radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

